Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s ‘COVID Pill’ Shows Promise, But Mortality Benefits Will Be Hard To Prove

Accurate Viral Test Shows Drug’s Promise

Executive Summary

Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about Roche's deal-making in a pandemic, coronavirus vaccine disinformation, Amgen’s Five Prime acquisition, a Novartis clinical trial failure, and new data for a Merck antiviral for the coronavirus.

Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance

Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.

Vaccitech Prepares For IPO, But AZ COVID-19 Vaccine Safety Fears Cloud Launch

The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143953

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel